Skip to main content
SpringerLink
Log in
Book cover

Energy Balance and Hematologic Malignancies pp 71–95Cite as

Obesity and Multiple Myeloma

  • Chapter
  • First Online:

Part of the book series: Energy Balance and Cancer ((EBAC,volume 5))

Abstract

Multiple myeloma (MM) is a plasma B-cell malignancy that is characterized by the presence of clonal proliferation of malignant plasma cells in the bone marrow, monoclonal protein in blood or urine, and organ dysfunction. It accounts for 10% of hematological malignancies and approximately 1% of all cancers in the USA. Several etiologic agents are associated with its development. Notably, obesity is consistently associated with increased risk and drives mechanistic pathways important in its development. In addition to age, black or African American heritage is a consistent risk factor as is male gender. Epidemiologic evidence on causes and biologic pathways supporting the obesity relation are presented. Diagnosis and treatment of MM patients are considered in the context of obesity as a cause with potential impact on treatment and outcomes among those with disease.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO (2001) Overweight as an avoidable cause of cancer in Europe. Int J Cancer 91(3):421–430

    Article  PubMed  CAS  Google Scholar 

  2. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. Br Med J 335(7630):1134

    Article  Google Scholar 

  3. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625–1638

    Article  PubMed  Google Scholar 

  4. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578

    Article  PubMed  Google Scholar 

  5. Wolin KY, Carson K, Colditz GA (2010) Obesity and cancer. Oncologist 15(6):556–565

    Article  PubMed  Google Scholar 

  6. Adams TD, Gress RE, Smith SC et al (2007) Long-term mortality after gastric bypass surgery. N Engl J Med 357(8):753–761

    Article  PubMed  CAS  Google Scholar 

  7. Sjostrom L, Narbro K, Sjostrom CD et al (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357(8):741–752

    Article  PubMed  Google Scholar 

  8. Lichtman MA (2010) Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist 15(10):1083–1101

    Article  PubMed  Google Scholar 

  9. International Agency for Research on Cancer (2002) Weight control and physical activity, vol 6. International Agency for Research on Cancer, Lyon

    Google Scholar 

  10. Wolin KY, Yan Y, Colditz GA (2011) Physical activity and risk of colon adenoma: a meta-analysis. Br J Cancer 104(5):882–885

    Article  PubMed  CAS  Google Scholar 

  11. Wolin KY, Yan Y, Colditz GA, Lee IM (2009) Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer 100(4):611–616

    Article  PubMed  CAS  Google Scholar 

  12. Fair AM, Montgomery K (2009) Energy balance, physical activity, and cancer risk. Methods Mol Biol 472:57–88

    Article  PubMed  Google Scholar 

  13. McTiernan A (2008) Mechanisms linking physical activity with cancer. Nat Rev Cancer 8(3):205–211

    Article  PubMed  CAS  Google Scholar 

  14. Birmann BM, Giovannucci E, Rosner B, Anderson KC, Colditz GA (2007) Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 16(7):1474–1478

    Article  PubMed  Google Scholar 

  15. Wolf A, Hunter D, Colditz GA et al (1994) Reproducibility and validity of a self-administered physical activity questionnaire. Int J Epidemiol 23:991–999

    Article  PubMed  CAS  Google Scholar 

  16. Chasan-Taber S, Rimm EB, Stampfer MJ et al (1996) Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology 7:81–86

    Article  PubMed  CAS  Google Scholar 

  17. Khan MM, Mori M, Sakauchi F, Matsuo K, Ozasa K, Tamakoshi A (2006) Risk factors for multiple myeloma: evidence from the Japan Collaborative Cohort (JACC) study. Asian Pac J Cancer Prev 7(4):575–581

    PubMed  CAS  Google Scholar 

  18. Kyle RA, Rajkumar SV (2007) Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol 20(4):637–664

    Article  PubMed  CAS  Google Scholar 

  19. North Dakota Cancer Registry (2007) Cancer fact sheet multiple myeloma. North Dakota Department of Health, Bismarck

    Google Scholar 

  20. Alexander DD, Mink PJ, Adami HO et al (2007) Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 120(Suppl 12):40–61

    Article  PubMed  CAS  Google Scholar 

  21. Kumar S (2010) Multiple myeloma—current issues and controversies. Cancer Treat Rev 36(Suppl 2):S3–11

    Article  PubMed  Google Scholar 

  22. Brenner H, Gondos A, Pulte D (2009) Expected long-term survival of patients diagnosed with multiple myeloma in 2006–2010. Haematologica 94(2):270–275

    Article  PubMed  Google Scholar 

  23. Altekreuse SFKC, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds) (2010) SEER cancer statistics review, 1975–2007. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SSEER data submission, posted to the SEER Web site

  24. Blade J, Rosinol L, Cibeira MT, de Larrea CF (2008) Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia 22(9):1651–1657

    Article  PubMed  CAS  Google Scholar 

  25. Blade J, Dimopoulos M, Rosinol L, Rajkumar SV, Kyle RA (2010) Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J Clin Oncol 28(4):690–697

    Article  PubMed  CAS  Google Scholar 

  26. Pettersson T, Konttinen YT (2010) Amyloidosis-recent developments. Semin Arthritis Rheum 39(5):356–368

    Article  PubMed  CAS  Google Scholar 

  27. Louw VJ, Webb MJ (2010) Prognosis and treatment of Waldenstrom’s macroglobulinemia. Transfus Apher Sci 42(2):193–197

    Article  PubMed  Google Scholar 

  28. Vijay A, Gertz MA (2007) Waldenstrom macroglobulinemia. Blood 109(12):5096–5103

    Article  PubMed  CAS  Google Scholar 

  29. Henry T, Fonseca R (2007) Genomics and proteomics in multiple myeloma and Waldenstrom macroglobulinemia. Curr Opin Hematol 14(4):369–374

    Article  PubMed  Google Scholar 

  30. Gertz MA, Fonseca R, Rajkumar SV (2000) Waldenstrom’s macroglobulinemia. Oncologist 5(1):63–67

    Article  PubMed  CAS  Google Scholar 

  31. Nau KC, Lewis WD (2008) Multiple myeloma: diagnosis and treatment. Am Fam Physician 78(7):853–859

    PubMed  Google Scholar 

  32. Lynch HT, Sanger WG, Pirruccello S, Quinn-Laquer B, Weisenburger DD (2001) Familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst 93(19):1479–1483

    Article  PubMed  CAS  Google Scholar 

  33. Altieri A, Chen B, Bermejo JL, Castro F, Hemminki K (2006) Familial risks and temporal incidence trends of multiple myeloma. Eur J Cancer 42(11):1661–1670

    Article  PubMed  Google Scholar 

  34. Coleman EA, Lynch H, Enderlin C et al (2009) Initial report of a family registry of multiple myeloma. Cancer Nurs 32(6):456–464

    Article  PubMed  Google Scholar 

  35. McDuffie HH, Pahwa P, Karunanayake CP, Spinelli JJ, Dosman JA (2009) Clustering of cancer among families of cases with Hodgkin Lymphoma (HL), Multiple Myeloma (MM), Non-Hodgkin’s Lymphoma (NHL), Soft Tissue Sarcoma (STS) and control subjects. BMC Cancer 9:70

    Article  PubMed  Google Scholar 

  36. Waxman AJ, Mink PJ, Devesa SS et al (2010) Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116(25):5501–5506

    Article  PubMed  CAS  Google Scholar 

  37. Landgren O, Weiss BM (2009) Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 23(10):1691–1697

    Article  PubMed  CAS  Google Scholar 

  38. Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78(1):21–33

    Article  PubMed  Google Scholar 

  39. (2009) StatBite: Multiple myeloma and African Americans: higher incidence but fewer autologous stem cell transplants. J Natl Cancer Inst 101(23):1610

    Google Scholar 

  40. Polednak AP (1994) Trends in cancer incidence in Connecticut, 1935–1991. Cancer 74(10):2863–2872

    Article  PubMed  CAS  Google Scholar 

  41. Devesa SS, Silverman DT, Young JL Jr et al (1987) Cancer incidence and mortality trends among whites in the United States, 1947–84. J Natl Cancer Inst 79(4):701–770

    PubMed  CAS  Google Scholar 

  42. National Cancer Institute (1975–2007) Surveillance epidemiology and end results (SEER) program. Incidence. National Cancer Institute, Bethesda, MD

    Google Scholar 

  43. Friedman GD, Herrinton LJ (1994) Obesity and multiple myeloma. Cancer Causes Control 5(5):479–483

    Article  PubMed  CAS  Google Scholar 

  44. Brown LM, Gridley G, Pottern LM et al (2001) Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. Cancer Causes Control 12(2):117–125

    Article  PubMed  CAS  Google Scholar 

  45. Blair CK, Cerhan JR, Folsom AR, Ross JA (2005) Anthropometric characteristics and risk of multiple myeloma. Epidemiology 16(5):691–694

    Article  PubMed  Google Scholar 

  46. MacInnis RJ, English DR, Hopper JL, Giles GG (2005) Body size and composition and the risk of lymphohematopoietic malignancies. J Natl Cancer Inst 97(15):1154–1157

    Article  PubMed  Google Scholar 

  47. Oh SW, Yoon YS, Shin SA (2005) Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 23(21):4742–4754

    Article  PubMed  Google Scholar 

  48. Engeland A, Tretli S, Hansen S, Bjorge T (2007) Height and body mass index and risk of lymphohematopoietic malignancies in two million Norwegian men and women. Am J Epidemiol 165(1):44–52

    Article  PubMed  Google Scholar 

  49. Fernberg P, Odenbro A, Bellocco R et al (2007) Tobacco use, body mass index, and the risk of leukemia and multiple myeloma: a nationwide cohort study in Sweden. Cancer Res 67(12):5983–5986

    Article  PubMed  CAS  Google Scholar 

  50. Britton JA, Khan AE, Rohrmann S et al (2008) Anthropometric characteristics and non-Hodgkin’s lymphoma and multiple myeloma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Haematologica 93(11):1666–1677

    Article  PubMed  Google Scholar 

  51. Pylypchuk RD, Schouten LJ, Goldbohm RA, Schouten HC, van den Brandt PA (2009) Body mass index, height, and risk of lymphatic malignancies: a prospective cohort study. Am J Epidemiol 170(3):297–307

    Article  PubMed  Google Scholar 

  52. Soderberg KC, Kaprio J, Verkasalo PK et al (2009) Overweight, obesity and risk of haematological malignancies: a cohort study of Swedish and Finnish twins. Eur J Cancer 45(7): 1232–1238

    Article  PubMed  Google Scholar 

  53. De Roos AJ, Ulrich CM, Ray RM et al (2010) Intentional weight loss and risk of lymphohematopoietic cancers. Cancer Causes Control 21(2):223–236

    Article  PubMed  Google Scholar 

  54. Kanda J, Matsuo K, Inoue M et al (2010) Association of anthropometric characteristics with the risk of malignant lymphoma and plasma cell myeloma in a Japanese population: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 19(6):1623–1631

    Article  PubMed  CAS  Google Scholar 

  55. Lu Y, Sullivan-Halley J, Henderson KD et al (2010) Anthropometric characteristics and multiple myeloma risk. Epidemiology 21(2):272–273

    Article  PubMed  Google Scholar 

  56. Troy J, Hartge P, Weissfeld J et al (2010) The relationship between anthropometry, cigarette smoking, alcohol consumption and non-hodgkin lymphoma in the PLCO trial. Am J Epidemiol 171(12):1270–1281

    Article  PubMed  Google Scholar 

  57. Wallin A, Larsson SC (2011) Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies. Eur J Cancer 47(11):1606–1615

    Article  PubMed  Google Scholar 

  58. Must A, Willett WC, Dietz WH (1993) Remote recall of childhood height, weight, and body build by elderly subjects. Am J Epidemiol 138(1):56–64

    PubMed  CAS  Google Scholar 

  59. Baer HJ, Tworoger SS, Hankinson SE, Willett WC (2010) Body fatness at young ages and risk of breast cancer throughout life. Am J Epidemiol 171(11):1183–1194

    Article  PubMed  Google Scholar 

  60. Landgren O, Rajkumar SV, Pfeiffer RM et al (2010) Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood 116(7):1056–1059

    Article  PubMed  CAS  Google Scholar 

  61. Brodt P, Samani A, Navab R (2000) Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol 60(8):1101–1107

    Article  PubMed  CAS  Google Scholar 

  62. Samani AA, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28(1):20–47

    Article  PubMed  CAS  Google Scholar 

  63. Roberts DL, Dive C, Renehan AG (2010) Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 61:301–316

    Article  PubMed  CAS  Google Scholar 

  64. Hankinson SE, Willett WC, Colditz GA et al (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113):1393–1396

    Article  PubMed  CAS  Google Scholar 

  65. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO (1997) Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76(9):1115–1118

    Article  PubMed  CAS  Google Scholar 

  66. Ma J, Pollak MN, Giovannucci E et al (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91(7):620–625

    Article  PubMed  CAS  Google Scholar 

  67. Chen W, Wang S, Tian T et al (2009) Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet 17(12):1668–1675

    Article  PubMed  CAS  Google Scholar 

  68. Rinaldi S, Cleveland R, Norat T et al (2010) Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer 126(7):1702–1715

    PubMed  CAS  Google Scholar 

  69. Birmann BM, Tamimi RM, Giovannucci E et al (2009) Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 18(1):282–288

    Article  PubMed  CAS  Google Scholar 

  70. Berenson JR, Sjak-Shie NN, Vescio RA (2000) The role of human and viral cytokines in the pathogenesis of multiple myeloma. Semin Cancer Biol 10(5):383–391

    Article  PubMed  CAS  Google Scholar 

  71. German AJ, Ryan VH, German AC, Wood IS, Trayhurn P (2010) Obesity, its associated disorders and the role of inflammatory adipokines in companion animals. Vet J 185(1):4–9

    Article  PubMed  CAS  Google Scholar 

  72. Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11(2):85–97

    Article  PubMed  CAS  Google Scholar 

  73. Rose DP (1997) Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies. Am J Clin Nutr 66(6 Suppl):1513S–1522S

    PubMed  CAS  Google Scholar 

  74. Rose DP, Connolly JM (1999) Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 83(3):217–244

    Article  PubMed  CAS  Google Scholar 

  75. Rose DP, Connolly JM (1997) Dietary fat and breast cancer metastasis by human tumor xenografts. Breast Cancer Res Treat 46(2–3):225–237

    Article  PubMed  CAS  Google Scholar 

  76. Legakis I, Syrigos K (2010) Obesity modulation—the role in carcinogenesis. Anticancer Agents Med Chem 10(6):481–490

    PubMed  CAS  Google Scholar 

  77. Mouzaki A, Panagoulias I, Dervilli Z et al (2009) Expression patterns of leptin receptor (OB-R) isoforms and direct in vitro effects of recombinant leptin on OB-R, leptin expression and cytokine secretion by human hematopoietic malignant cells. Cytokine 48(3):203–211

    Article  PubMed  CAS  Google Scholar 

  78. Reseland JE, Reppe S, Olstad OK et al (2009) Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma. Eur J Haematol 83(5):460–470

    Article  PubMed  CAS  Google Scholar 

  79. Pamuk GE, Demir M, Harmandar F, Yesil Y, Turgut B, Vural O (2006) Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristics. Exp Oncol 28(3):241–244

    PubMed  CAS  Google Scholar 

  80. Dalamaga M, Karmaniolas K, Panagiotou A et al (2009) Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case–control study. Cancer Causes Control 20(2):193–199

    Article  PubMed  Google Scholar 

  81. Kelesidis I, Kelesidis T, Mantzoros CS (2006) Adiponectin and cancer: a systematic review. Br J Cancer 94(9):1221–1225

    Article  PubMed  CAS  Google Scholar 

  82. Housa D, Housova J, Vernerova Z, Haluzik M (2006) Adipocytokines and cancer. Physiol Res 55(3):233–244

    PubMed  CAS  Google Scholar 

  83. Petridou E, Mantzoros C, Dessypris N et al (2003) Plasma adiponectin concentrations in relation to endometrial cancer: a case–control study in Greece. J Clin Endocrinol Metab 88(3):993–997

    Article  PubMed  CAS  Google Scholar 

  84. Petridou E, Mantzoros CS, Dessypris N, Dikalioti SK, Trichopoulos D (2006) Adiponectin in relation to childhood myeloblastic leukaemia. Br J Cancer 94(1):156–160

    Article  PubMed  CAS  Google Scholar 

  85. Mantzoros C, Petridou E, Dessypris N et al (2004) Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89(3):1102–1107

    Article  PubMed  CAS  Google Scholar 

  86. Wei EK, Giovannucci E, Selhub J, Fuchs CS, Hankinson SE, Ma J (2005) Plasma vitamin B6 and the risk of colorectal cancer and adenoma in women. J Natl Cancer Inst 97(9):684–692

    Article  PubMed  CAS  Google Scholar 

  87. Tilg H, Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6(10):772–783

    Article  PubMed  CAS  Google Scholar 

  88. Wozniak SE, Gee LL, Wachtel MS, Frezza EE (2009) Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 54(9):1847–1856

    Article  PubMed  Google Scholar 

  89. Klein B, Zhang XG, Lu ZY, Bataille R (1995) Interleukin-6 in human multiple myeloma. Blood 85(4):863–872

    PubMed  CAS  Google Scholar 

  90. Gado K, Domjan G, Hegyesi H, Falus A (2000) Role of Interleukin-6 in the pathogenesis of multiple myeloma. Cell Biol Int 24(4):195–209

    Article  PubMed  CAS  Google Scholar 

  91. Cozen W, Gebregziabher M, Conti DV et al (2006) Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev 15(11):2285–2291

    Article  PubMed  CAS  Google Scholar 

  92. Tzanavari T, Giannogonas P, Karalis KP (2010) TNF-alpha and obesity. Curr Dir Autoimmun 11:145–156

    Article  PubMed  CAS  Google Scholar 

  93. Hideshima T, Podar K, Chauhan D, Anderson KC (2005) Cytokines and signal transduction. Best Pract Res Clin Haematol 18(4):509–524

    Article  PubMed  CAS  Google Scholar 

  94. Christoulas D, Terpos E, Dimopoulos MA (2009) Pathogenesis and management of myeloma bone disease. Expert Rev Hematol 2(4):385–398

    Article  PubMed  Google Scholar 

  95. Baker RG, Hayden MS, Ghosh S (2011) NF-kappaB, inflammation, and metabolic disease. Cell Metab 13(1):11–22

    Article  PubMed  CAS  Google Scholar 

  96. Oancea M, Mani A, Hussein MA, Almasan A (2004) Apoptosis of multiple myeloma. Int J Hematol 80(3):224–231

    Article  PubMed  CAS  Google Scholar 

  97. Li ZW, Chen H, Campbell RA, Bonavida B, Berenson JR (2008) NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol 15(4):391–399

    Article  PubMed  CAS  Google Scholar 

  98. Choi SJ, Cruz JC, Craig F et al (2000) Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96(2):671–675

    PubMed  CAS  Google Scholar 

  99. Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY (2003) Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 101(9):3568–3573

    Article  PubMed  CAS  Google Scholar 

  100. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106(1):296–303

    Article  PubMed  CAS  Google Scholar 

  101. Liu X, Tang Z, Zou P (2000) Bcl-1 rearrangement and cyclin D1 protein expression in multiple myeloma precursor cells. J Tongji Med Univ 20(2):128–131, 136

    Google Scholar 

  102. Demchenko Y, Glebov O, Zingone A, Keats J, Bergsagel P, Kuehl W (2010) Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 115(17):3541–3552

    Article  PubMed  CAS  Google Scholar 

  103. Klein B (2010) Positioning NK-kappaB in multiple myeloma. Blood 115(17):3422–3424

    Article  PubMed  CAS  Google Scholar 

  104. Bernard M, Bancos S, Sime P, Phipps R (2008) Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr Pharm Des 14:2051–2060

    Article  PubMed  CAS  Google Scholar 

  105. Ladetto M, Vallet S, Trojan A et al (2005) Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 105(12):4784–4791

    Article  PubMed  CAS  Google Scholar 

  106. Kawano M, Hirano T, Matsuda T et al (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332(6159):83–85

    Article  PubMed  CAS  Google Scholar 

  107. Bergsagel P, Kuehl W (2003) Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev 194:96–104

    Article  PubMed  CAS  Google Scholar 

  108. Naugler W, Karin M (2008) NF-Κ B and cancer—identifying the targets and mechanisms. Curr Opin Genet Dev 18:19–26

    Article  PubMed  CAS  Google Scholar 

  109. Chang E (2004) Aspirin and the risk of Hodgkin’s lymphoma in a population-based case–control study. J Natl Cancer Inst 96:305–315

    Article  PubMed  CAS  Google Scholar 

  110. Chang E (2010) Aspirin and other nonsteroidal anti-inflammatory drugs in relation to Hodgkin lymphoma risk in northern Denmark. Cancer Epidemiol Biomark Prev 19:59–64

    Article  CAS  Google Scholar 

  111. Flick ED, Chan KA, Bracci PM, Holly EA (2006) Use of nonsteroidal antiinflammatory drugs and non-Hodgkin lymphoma: a population-based case–control study. Am J Epidemiol 164(5):497–504

    Article  PubMed  Google Scholar 

  112. Zhang Y, Holford TR, Leaderer B et al (2004) Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 15(4):419–428

    Article  PubMed  Google Scholar 

  113. Cuzick J, Otto F, Baron J et al (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10:501–507

    Article  PubMed  CAS  Google Scholar 

  114. Rothwell P, Wilson M, Elwin C et al (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376(9754):1741–1750

    Article  PubMed  CAS  Google Scholar 

  115. Landgren O, Zhang Y, Zahm SH, Inskip P, Zheng T, Baris D (2006) Risk of multiple myeloma following medication use and medical conditions: a case–control study in Connecticut women. Cancer Epidemiol Biomarkers Prev 15(12):2342–2347

    Article  PubMed  CAS  Google Scholar 

  116. Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351(18):1860–1873

    Article  PubMed  CAS  Google Scholar 

  117. Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364(11):1046–1060

    Article  PubMed  CAS  Google Scholar 

  118. Durie BG, Kyle RA, Belch A et al (2003) Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 4(6):379–398

    Article  PubMed  Google Scholar 

  119. Higgins MJ, Fonseca R (2005) Genetics of multiple myeloma. Best Pract Res Clin Haematol 18(4):525–536

    Article  PubMed  CAS  Google Scholar 

  120. Terpos E, Eleutherakis-Papaiakovou V, Dimopoulos MA (2006) Clinical implications of chromosomal abnormalities in multiple myeloma. Leuk Lymphoma 47(5):803–814

    Article  PubMed  CAS  Google Scholar 

  121. Drach J, Kaufmann H, Urbauer E, Schreiber S, Ackermann J, Huber H (2000) The biology of multiple myeloma. J Cancer Res Clin Oncol 126(8):441–447

    Article  PubMed  CAS  Google Scholar 

  122. Van Marion AMW, Lokhorst HM, van den Tweel JG (2003) Pathology of multiple myeloma. Curr Diagn Pathol 9:322–327

    Article  Google Scholar 

  123. Tonon G (2007) Molecular pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 21(6):985–1006, vii

    Google Scholar 

  124. Cheymol G (2000) Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 39(3):215–231

    Article  PubMed  CAS  Google Scholar 

  125. Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71–87

    Article  PubMed  CAS  Google Scholar 

  126. Navarro WH (2003) Impact of obesity in the setting of high-dose chemotherapy. Bone Marrow Transplant 31(11):961–966

    Article  PubMed  CAS  Google Scholar 

  127. Rosner GL, Hargis JB, Hollis DR et al (1996) Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 14(11):3000–3008

    PubMed  CAS  Google Scholar 

  128. Vogl DT, Wang T, Perez WS et al (2011) Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 17(12):1765–1774

    Article  PubMed  Google Scholar 

  129. Nikolousis E, Nagra S, Paneesha S et al (2010) Allogeneic transplant outcomes are not affected by body mass index (BMI) in patients with haematological malignancies. Ann Hematol 89(11):1141–1145

    Article  PubMed  Google Scholar 

  130. Liberopoulos EN, Mikhailidis DP, Elisaf MS (2005) Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 6(4):283–296

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Supported by U54CA155496, U54CA153460, and RO1CA127435.

Author information

Authors and Affiliations

  1. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, 63110, USA

    Tracey Beason Ph.D., M.S.P.H

  2. Chief Division of Public Health Sciences, Department of Surgery, Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, 63110, USA

    Graham Colditz M.D., Dr. P.H

Authors
  1. Tracey Beason Ph.D., M.S.P.H
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Graham Colditz M.D., Dr. P.H
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tracey Beason Ph.D., M.S.P.H .

Editor information

Editors and Affiliations

  1. Keck School of Medicine, Sunset Blvd., MS #61 4650, Los Angeles, 90027, California, USA

    Steven D. Mittelman

  2. School of Medicine, Center for Science, Health & Society, Case Western Reserve University, Euclid Ave. 10900, Cleveland, 44106, Ohio, USA

    Nathan A. Berger

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Beason, T., Colditz, G. (2012). Obesity and Multiple Myeloma. In: Mittelman, S., Berger, N. (eds) Energy Balance and Hematologic Malignancies. Energy Balance and Cancer, vol 5. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-2403-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-2403-1_4

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-2402-4

  • Online ISBN: 978-1-4614-2403-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation